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Weili Wang, Stefan Pçhlmann, W. Bruce Turnbull, and Dejian Zhou*
Abstract: A highly efficient cap-exchange approach for
preparing compact, dense polyvalent mannose-capped quan-
tum dots (QDs) has been developed. The resulting QDs have
been successfully used to probe multivalent interactions of
HIV/Ebola receptors DC-SIGN and DC-SIGNR (collectively
termed as DC-SIGN/R) using a sensitive, ratiometric Fçrster
resonance energy transfer (FRET) assay. The QD probes
specifically bind DC-SIGN, but not its closely related receptor
DC-SIGNR, which is further confirmed by its specific blocking
of DC-SIGN engagement with the Ebola virus glycoprotein.
Tuning the QD surface mannose valency reveals that DC-
SIGN binds more efficiently to densely packed mannosides. A
FRET-based thermodynamic study reveals that the binding is
enthalpy-driven. This work establishes QD FRET as a rapid,
sensitive technique for probing structure and thermodynamics
of multivalent protein–ligand interactions.
Over the past 15 years, quantum dot (QD) Fçrster reso-
nance energy transfer (FRET) technology has emerged as
a powerful tool to address a broad range of biomedical
questions because it combines the spectroscopic ruling ability
of FRET and the stable, bright fluorescence of QDs.[1] It has
been widely used for bio-/enzymatic/environmental/intracel-
lular sensing, bio-diagnostics, cell monitoring and tracking.[1,2]
Despite great progress, QD FRET has not been applied to
probe multivalent protein–ligand interactions which are
widespread and crucial for many important biological
events such as viral infection, immune response, cell signaling,
and its regulation.[3] This limitation is primarily due to a lack
of an effective approach to prepare compact (hydrodynamic
diameter, Dh< 10 nm), biocompatible and dense polyvalent
QDs which are essential for multivalent binding and sensitive
FRET readout.[1b] Compact, biocompatible QDs have been
prepared by cap-exchange using dihydrolipoic acid (DHLA)
based ligands for sensing and imaging applications.[4] The
requirement of using a large excess of ligand (e.g. ligand:QD
molar ratio of 104–105 :1) of current protocols,[4] however,
makes it impractical to initiate direct QD cap-exchange using
expensive custom ligands. Thus functional groups are mostly
conjugated to cap-exchanged QDs using various coupling and
bioconjugation approaches. It has been difficult to achieve
high polyvalency (> 150) on compact, sub-10 nmQDs. Herein
we have solved this problem by performing cap-exchange in
a homogeneous solution using functional ligands appending
a deprotonated DHLA moiety. Our approach greatly
improved the cap-exchange efficiency, allowing for produc-
tion of compact, dense polyvalent mannose-capped QDs
using 20–200 fold less ligand than literature protocols. We
demonstrate that such compact, polyvalent mannose-capped
QDs can provide quantitative binding affinity and thermody-
namic parameters for multivalent protein–glycan interactions
underpinning HIV/Ebola viral infections through a sensitive,
ratiometric FRET readout strategy.
Here the dendritic cell receptor, DC-SIGN (one of the
most important cell pathogen receptors)[5] and an endothelial
cell receptor, DC-SIGNR, were employed as model multi-
meric proteins. These proteins recognize multiple mannose-
containing glycans on the human immunodeficiency virus
(HIV) and Ebola virus (EBOV) surface glycoproteins via
their clustered carbohydrate-recognition-domains (CRDs,
Figure 1E).[5] The resulting high affinity, multivalent binding
can enhance viral infectivity. It is known that synthetic
multivalent glycoconjugates can inhibit such interactions.[6]
Despite sharing 77% amino acid identity and an overall
tetrameric structure, DC-SIGN/R have shown to possess
notable differences in glycan binding affinity, specificity and
viral transmission efficiency. For example, DC-SIGN recog-
nizes and transmits some HIV strains more effectively than
DC-SIGNR,[7] whereas only DC-SIGNR promotes West Nile
Virus (WNV) infection with high efficiency.[8] Given individ-
ual CRD–mannose binding motifs are identical in DC-SIGN/
R[5b] and the binding affinities are very weak (KDmm),
[9]
such differences must stem from their different multivalent
binding properties which are still poorly understood. We
reasoned that a polyvalent mannose–QD conjugate would be
useful for probing the CRD arrangements here because it
combines features of weak individual CRD–mannose binding
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affinity and nanoscale spherical geometry. As a result, only
the protein with CRDs facing the same direction can bind to
the QD multivalently, leading to high affinity.
First, two multifunctional mannose-containing ligands
were designed and synthesized (see the Supporting Informa-
tion for details). Each ligand comprises a DHLA moiety for
strong chelative binding to QD surface Zn2+ ions; a poly(eth-
ylene glycol), PEG, linker for resisting non-specific adsorp-
tion and imposing high stability and biocompatibility;[4] and
a mannose residue for specific protein binding (abbreviated
as DHLA-PEGn-Man hereafter, where n= 3 or about 13
stands for uniform or mixed length linker containing 3 or an
average of 13 PEG units, respectively, Figure 1A).
The DHLA-PEGn-Man ligands were subsequently
employed to perform cap-exchange with hydrophobic CdSe/
ZnSQDs (4.2 nm diameter, lEM ca. 560 nm; see Figure S1A in
the Supporting Information) to make QD-PEGn-Man probes.
Cap-exchange was performed in homogenous solution (e.g.
1:1 v/v CHCl3/MeOH) using deprotonated DHLA to facili-
tate the ligand exchange process and enhance their QD
binding affinity because thiolates bind much more strongly to
Zn2+ ions than thiols (see Section A4 in the Supporting
Information).[4a]Under such conditions, stable, biocompatible
QD-PEGn-Mans were readily prepared at a ligand:QD molar
ratio of 500:1, a substantial 20–200 fold lower than literature
protocols. Importantly, this improvement made it practical to
directly initiate cap-exchange with hydrophobic QDs using
precious functional mannose ligands. It also enabled us to
achieve unprecedented levels of high glycan polyvalency (ca.
330 70 and 170 30 for QD-EG3-Man and QD-PEG13-
Man) on compact sub-10 nm QDs (Figure S1). This would be
very difficult for other current literature methods. Further-
more, this method also facilitated tuning the density and
spacing of glycans at the QD surface by dilution with
a DHLA-zwitterion ligand (Figure 1D). These advantageous
properties made the QDs powerful FRET probes for inves-
tigating multivalent protein–glycan interactions for the first
time. Interestingly, the average inter-Man distance in the QD-
EG3-Man was estimated as about 0.98 nm (see Section A43 in
the Supporting Information), matching well to the inter-
glycosylation spacing of about 1 nm found on the HIV surface
glycoprotein, gp120.[10]
To probe the multivalent binding by FRET, DC-SIGN
was labeled with Atto-594 dye (Section A51/52) on a site-
specifically introduced cysteine residue. The dye labeling did
not affect its specific binding to a Sepharose-mannose
column. The Atto-594-QD FRET pair had a respectable
Fçrster radius (R0= 4.7/5.0 nm for QD-EG3-Man/QD-PEG13-
Man, respectively; see Figure S2). Binding of the labeled DC-
SIGN to the QDs yielded significantly reduced QD fluores-
cence at 554 nm together with concurrently enhanced Atto-
594 FRET signal at 626 nm (Figure 2A,B), which was fully
consistent with a QD-sensitized Atto-594 FRET mechanism.
Stronger FRET signals and more severely quenched QD
fluorescence were observed for DC-SIGN binding to QD-
EG3-Man over QD-PEG13-Man, indicating more efficient
FRET in the former pair. Both bindings displayed excellent
fits (R2> 0.99) by the single QD donor FRETwith N identical
acceptors model,[2] yielding QD–dye distances (r) of about
6.8/9.8 nm for QD-EG3-Man/QD-PEG13-Man, respectively
(Figure S3). These r values roughly matched the sum of QD
core radius plus respective fully extended ligand length (ca.
6.5 and 10.0 nm; Figure S1).
The observed FRET signal was completely diminished in
the absence of Ca2+ (Figure S4), suggesting the signal was
indeed the result of Ca2+-dependent DC-SIGN-mannose
binding.[11] Moreover, the FRET signal was effectively
inhibited by free mannose in a dose-dependent manner,
while galactose was much less effective at inhibiting this
binding (Figure S5). This result agrees well with DC-SIGNÏs
binding specificity for mannose over galactose.[11a] A higher
mannose concentration (KI) was required to inhibit DC-
SIGN binding to QD-EG3-Man than to QD-PEG13-Man (1.4
vs. 0.80 mm, see Table 1), which was consistent with the
former binding being tighter (apparent KD 0.32 vs. 0.6 mm).
Surprisingly, binding of DC-SIGNR (also labeled with
Atto-594, Section A51) to the QDs yielded only very weak
FRET signals (Figure 2C and D) which were barely stronger
than that of the monomeric CRD (Figure 2E) or non-specific
interaction between DC-SIGN/R and a DHLA-ZW-capped
control QD (Figure S6), suggesting minimal binding. Despite
Figure 1. A) Chemical structure of the dihydrolipoic acid–poly(ethylene
glycol)–mannose (DHLA-PEGn-Man) ligands and the schematic of our
ligand exchange approach using mannose-capped quantum dots.
B,C,D) Tuning interglycan spacing by a PEG linker length of DHLA-
PEGn-Man [n13 (B) or 3 (C)] and diluting with a DHLA-zwitterion
spacer ligand (D). E) Cartoon of probing multivalent interactions
between extracellular segment of DC-SIGN/R and QD-PEGn-Man by
FRET.
Table 1: Biophysical and thermodynamic parameters of the DC-SIGN-
QD interactions.
QD probe Apparent
KD [mm]
KI
[mm][a]
DH
[kJmol¢1]
DS
[J K¢1mol¢1]
QD-PEG13-Man 0.60.1 0.80.1 ¢441 ¢402
QD-EG3-Man 0.320.07 1.40.1 ¢566 ¢5518
[a] Inhibition constant of DC-SIGN-QD binding by free mannose.
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some degree of QD quenching being observed for the DC-
SIGNR and control samples, the specific QD-DC-SIGN
binding was clearly distinguished from these controls through
analysis of the FRET ratio (I626/I554) which is linearly
correlated to the amounts of QD-bound proteins (Sec-
tion A55). The apparent FRET ratio for DC-SIGN followed
typical binding curves (Figure 2Fand SI, Table S1). However,
the signals for DC-SIGNR remained low and comparable to
non-specific interaction throughout the concentrations tested
(Figure S6G). In fact, the maximum I626/I554 value for DC-
SIGN binding to QD-PEG13-Man/ QD-EG3-Man was 12/60
times greater than that of the equivalent DC-SIGNR binding,
demonstrating a remarkable binding specificity of the QDs
for DC-SIGN over DC-SIGNR, two closely related tetra-
meric receptors having almost identical protein sequence. To
our knowledge, this level of DC-SIGN/R discrimination (ca.
60-fold) is unprecedented for polyvalent ligands built upon
such simple carbohydrates. This work thus demonstrates the
role of polyvalency in determining multivalent binding
selectivity, and opens up a new method for understanding
glycobiology where multivalent effects are absolutely essen-
tial to biological activity.
The QD-DC-SIGN binding specificity was further veri-
fied by a cell based assay. Here, a murine leukemia virus
(MLV) vector was used to deliver the luciferase gene to
human embryonic kidney cells (293T) previously transfected
to express DC-SIGN/R. The MLV vector bearing Ebola virus
glycoprotein (EBOV-GP) can bind to cell surface DC-SIGN/
R to augment cell entry and gene transduction.[5a,d]DC-SIGN/
R expression in cells markedly increased the gene trans-
duction efficiency. While QD-EG3-Man treatment signifi-
cantly reduced the gene transduction of DC-SIGN-positive
cells in a dose-dependent manner (Figure 2G), presumably
via binding to cell surface DC-SIGN, which blocked the
binding and entry of the EBOV-GP-bearing vector. In
contrast, gene transduction of cells expressing DC-SIGNR
was unaffected by QD-EG3-Man. This inhibiting specificity
matched perfectly with the QDÏs much higher affinity to DC-
SIGN over DC-SIGNR. Finally, QD-EG3-Man did not
modulate significantly the gene transduction of control cells
(pcDNA) nor the transduction driven by a control vector
bearing vesicular stomatitis virus glycoprotein (VSV-G)
which cannot use DC-SIGN/R for cell entry (Figure 2H).[5a,d]
These results confirmed that the specific QD-DC-SIGN
binding was responsible for the observed inhibition.
High mannose density appears to favor binding to DC-
SIGN over DC-SIGNR. Consistent with this, the high glycan
density on HIV (each gp120 contains 25 glycosylation sites)[10]
also favors DC-SIGN binding/transfection over WNV whose
glycoprotein contains just 1 glycosylation site.[12] Diluting the
QD surface DHLA-EG3-Man density with DHLA-ZW
strongly affected its DC-SIGN binding. The I626/I554 ratios all
increased linearly with the increasing protein concentration,
except for the 100%QD-EG3-Man at high concentration due
to surface binding saturation (Figure 3A). Since the I626/I554
ratio is linearly correlated to the amounts of QD-bound
proteins (Section A55), the slopes of the binding curves thus
represents the binding efficiency (or fraction of added
proteins that have bound to the QD). Note, not all added
Figure 2. A–E) Acceptor direct excitation background-corrected fluores-
cence spectra of QD-PEGn-Man (lEM=554 nm, final CQD=40 nm) after
binding to Atto-594-labeled proteins: A) DC-SIGN+QD-PEG13-Man;
B) DC-SIGN+QD-EG3-Man; C) DC-SIGNR+QD-PEG13-Man; D) DC-
SIGNR+QD-EG3-Man; E) DC-SIGN CRD monomer+QD-EG3-Man.
F) Relationship between the apparent FRET ratio (I626/I554) and protein
concentration fitted to the Hill equation. G,H) Luciferase activities of
cell lysates of DC-SIGN/R expressing 293T cells after exposure to an
Ebola virus glycoprotein-bearing, luciferase-encoding murine leukemia
virus (MLV-EBOV-GP) vector in the presence of indicated amounts of
QD-EG3-Man in Dulbecco’s modified eagle medium supplemented
with 10% fetal bovine serum. A MLV vector bearing the vesicular
stomatitis virus glycoprotein (MLV-VSV-G) was used as negative
control. Cells transfected with empty plasmid (pcDNA) were used as
additional negative controls. In panel (G), the reduction of EBOV-GP-
dependent transduction by 250 nm QD-EG3-Man was statistically
significant from the 0 nm QD control (p=0.024).
Figure 3. A) A plot of apparent FRET ratio (I626/I554) as a function of
DC-SIGN concentration for QD-EG3-Man capped with different per-
centage of DHLA-EG3-Man ligand: square (100%); cross (50%) and
triangle (25%). B) Normalized DC-SIGN binding efficiency per man-
nose for QD-EG3-Man at different surface mannose density.
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DC-SIGNs may bind to the QD due to natural binding/
dissociation equilibrium. The QD-DC-SIGN binding effi-
ciency was decreased rapidly with mannose ligand dilution
(Figure 3B), revealing a strong preference of DC-SIGN for
binding to multivalent ligands with a high mannose density.
The FRET ratio for DC-SIGN binding to both QDs was
found to decrease with increasing temperature (Figure S7).
Assuming that the maximum binding (ca. I626/I554) was
independent of temperature, then apparent KDs at each
temperature were obtained (Table S2). The binding thermo-
dynamic parameters were obtained from an Arrhenius data
analysis (Table 1). The QD-DC-SIGN binding was found to
be enthalpy driven, with QD-EG3-Man giving greater neg-
ative enthalpy and entropy changes. Individual CRD–man-
nose binding was also found to be enthalpy-driven from an
isothermal titration calorimetry study.[9] Thus the same bind-
ing mechanism may be involved in the multivalent QD-DC-
SIGN binding.
The apparent KDs for DC-SIGN-QD binding were all in
the high nm range (Table 1), > 5000-fold tighter than individ-
ual mannose–CRD binding (KD= 3.5 mm),
[9] indicating that
multivalent binding greatly enhanced the binding affinity.
Because the mannose moieties are covalently coupled to
a solid, non-deformable and spherical QD core, only recep-
tors having CRDs that face in the same direction are able to
bind multivalently to the QD. The minimal DC-SIGNR-QD
binding revealed here implies an inability to form effective
multivalent binding. Based on their distinct QD-binding
properties, we propose that the CRDs are facing upwardly
along the coiled-coil axes in DC-SIGN (hence readily
accessible to multivalent binding to the QD), but sideways
in DC-SIGNR (hence unavailable to bind the QD multi-
valently, Figure 4). Such structural models agree well with
those proposed from small-angle X-ray scattering studies.[13]
The different CRD arrangement and accessibility in DC-
SIGN/R may account for their distinct viral binding/trans-
mission properties. It also correlates well with the biological
roles: the high accessibility of DC-SIGN should enable rapid
antigen capture to trigger the immune response as required
for an antigen-presenting dendritic cell surface endocytic
receptor.[11a,14] Whereas the endothelial cell surface adhesion
receptor DC-SIGNR[11a] may only recognize specific, spatial
and orientation-matched multivalent glycans.
In conclusion, an efficient ligand exchange approach for
making compact, biocompatible QDs densely capped with
specific glycans has been developed, enabling QD FRET to
be employed to probe multivalent receptor–glycan interac-
tions for the first time. Compared to other biophysical
techniques, QD FRET has the advantages of high sensitivity,
rapid, separation-free detection in solution, and ratiometric
readout signal, rendering detection highly robust and reliable.
It can provide quantitative binding thermodynamics and
reveal insights of binding site arrangement and accessibility in
multimeric proteins. In particular, we reveal that binding sites
arrangements in DC-SIGN and DC-SIGNR are functionally
distinct and only DC-SIGN binds efficiently to small,
spherical multivalent glycan ligands. We further demonstrate
that the polyvalent QD specifically inhibits DC-SIGN-, but
not DC-SIGNR-mediated pseudo-Ebola virus entry of target
cells in serum media. This work establishes a potential new
strategy for targeting DC-SIGN- from DC-SIGNR-mediated
viral infection.
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